Preclinical Imaging Market

Preclinical Imaging Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 2.8 billion and is projected to reach USD 4.7 billion by the completion of 2034.

Product Overview

Preclinical imaging is a branch of medical imaging that studies biological procedures and disorders in tiny animal models, like mice or rats, before performing human trials. Various imaging techniques, such as MRI, PET, CT, and optical imaging, are used to visualize anatomical features, molecular interactions, and physiological activities at the cellular and molecular levels. Additionally, scientists can use non-invasive imaging techniques to track the progression of disease, assess the efficacy of treatment, and study the underlying causes of illness. Preclinical imaging is important in drug development as it allows researchers to assess new treatments, along with understanding their pharmacokinetics and pharmacodynamics, and make informed decisions before moving on to human trials. As a result, preclinical imaging provides an important link between fundamental research and practical medical applications, as it helps in the transitioning of new treatments.

Market Highlights

Preclinical Imaging Market is expected to grow at a compound annual growth rate (CAGR) of 5% from 2024 to 2034

Preclinical Imaging Market is projected to reach USD 4.7 billion over the forecast period, due to the growth in research & development efforts in the pharmaceutical and biotechnology sectors. The enhanced technology of imaging modalities such as MRI, PET, SPECT, and CT has increased their ability to study molecular and cellular processes in small animal models. In addition, the rising need for personalized medicine and accurate treatments has led to high investment in preclinical imaging for drug discovery and development. Moreover, the increasing occurrence of chronic illnesses such as cancer and neurological disorders highlights the importance of gaining a deeper understanding of disease mechanisms, which further promotes the adoption of preclinical imaging. Therefore, the preclinical imaging market is expected to grow due to the growing use of advanced imaging technologies and the higher investment in biomedical research.

Source: Fatpos Global

Preclinical Imaging Market Segmentation

Optical Imaging segment will lead the industry as it offers outstanding sensitivity

Preclinical Imaging Market is divided by Product into Optical Imaging, PET, SPECT, Optical Imaging Reagents, Contrast Agents, and Nuclear Imaging Reagents. The optical imaging segment is expected to dominate the preclinical imaging market due to several factors. Optical imaging methods, such as bioluminescence and fluorescence imaging, offer excellent sensitivity for clear visualization of molecular and cellular operations in living organisms. This permits scientists to observe the development of diseases and analyze biological processes as they happen, thereby offering important data for preclinical studies. In addition, the wide variety of optical imaging reagents, such as fluorescent dyes and bioluminescent probes, adds to the effectiveness of optical imaging in preclinical research. As a result, the optical imaging sector will remain the leading segment in the preclinical imaging industry.

Oncology segment will dominate the market owing to the growing incidence of cancers

Preclinical Imaging Market is divided by Application into Oncology, Neurology, and Others. The oncology segment will maintain the highest market share as it is a prominent field of study due to the high occurrence and complexity of cancer. In addition, investments in preclinical studies are growing due to the need for effective cancer treatments to improve the understanding of the biology of tumors and create new therapies. Nonclinical imaging methods like MRI, PET, and optical imaging provide important information about the development and reaction of tumors for treatment in animal models. Furthermore, innovations in molecular imaging tools allow scientists to observe molecular activities linked to cancer, which results in the need for preclinical oncology imaging. Therefore, the dominance of the oncology segment displays the contribution of preclinical imaging to the development of cancer research and medication creation.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Advancements in Preclinical Imaging Technology to Drive Growth in the Preclinical Imaging Market

Developments in technology play a major role in fueling the adoption of the preclinical imaging market by improving the capabilities of imaging systems. Improvements in sensitivity and resolution of imaging allow researchers to learn about biological processes at the molecular and cellular levels. For instance, the growth of hybrid imaging systems, such as PET/CT or PET/MRI, is a major example. These systems combine modalities to help researchers connect functional data and improve the accuracy of preclinical research. Similarly, the use of multimodal imaging systems enables the concurrent collection of complementary data, which results in a comprehensive understanding of complex biological events. Furthermore, preclinical imaging is being used frequently, thanks to technical innovations, which have led to its acceptance in pharmaceutical and academic research facilities.

Increasing Prevalence of Chronic Diseases Act as a Catalyst for Market Growth

Increasing occurrence of chronic illnesses such as cancer and neurological disorders is pushing the need for preclinical imaging in research and drug development. The global burden of these diseases is continuously rising, as a result, there is an increasing focus on understanding the mechanisms of disease and creating specific treatments. In addition, preclinical imaging is important in this process as it allows researchers to see how diseases progress and understand the biological processes in animal models. In the field of oncology research, methods like MRI and PET imaging provide non-invasive tracking of tumor development and reaction to therapy. In the same way, MRI and CT imaging techniques help researchers explore the structure and function of the brain, which helps in creating new treatments for diseases such as Alzheimer's and Parkinson's.

Restraints

Cost of Equipment and Maintenance in the Preclinical Imaging Market Will Impact the Growth

Substantial financial investment for purchasing and maintaining imaging equipment is a limitation of the preclinical imaging market. The first investment required to purchase preclinical imaging equipment like MRI, PET, or CT scanners is enormous, with costs ranging from hundreds of thousands to millions of dollars. Moreover, costs associated with maintaining equipment further increase the ownership expenses. Thus, the high cost acts as a major obstacle for smaller research institutions and academic labs with tight budgets, which hinders their ability to adopt preclinical imaging technologies. Hence, the expensive equipment and maintenance can hinder market penetration in developing countries with restricted research funding and resources.

Recent Developments

• In May 2022, Bruker unveiled ground-breaking 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets as part of its renowned preclinical magnetic resonance imaging (MRI) systems range.
• In April 2022, PerkinElmer revealed the broadening of its in vivo imaging portfolio through the introduction of the Vega imaging system. This innovative ultrasound platform marks a significant advancement, blending hands-free, automated technology with high-throughput capability.

Preclinical Imaging Market

Key Players:

• Bruker Corporation
• PerkinElmer, Inc.
• Siemens Healthineers AG
• GE Healthcare
• MR Solutions
• Aspect Imaging Ltd.
• Mediso Medical Imaging Systems
• MILabs B.V.
• TriFoil Imaging
• Agilent Technologies, Inc.
• Fujifilm Holdings Corporation
• Thermo Fisher Scientific Inc.
• Miltenyi Biotec
• LI-COR Biosciences
• Perceptive Instruments Ltd.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Preclinical Imaging Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region is at the forefront of the preclinical imaging market due to its strong research & development infrastructure, which includes well-known pharmaceutical and biotechnology companies, academic institutions, and research organizations. These organizations create a strong demand for preclinical imaging technologies to help in drug discovery and development endeavors. In addition, the government of North America provides major funding and support for biomedical research.

In the meantime, the Asia Pacific region is closely following North America due to its quick economic growth and increasing need for advanced medical technologies. The need for advanced diagnostic and treatment options is driven by the high number of people and disease rates in the area, which forces leading pharmaceutical companies and research institutions to invest in preclinical imaging technologies across the Asia Pacific region.

Source: Fatpos Global

Impact of COVID-19 on the Preclinical Imaging Market

Preclinical imaging market experienced positive as well as negative effects due to the COVID-19 pandemic. Initially, the growth of the market was hampered by disruptions in research activities as labs were closed and non-essential research was limited. In addition, numerous pharmaceutical companies shifted their focus to COVID-19-related research, thereby affecting the funding for preclinical imaging in different therapeutic fields. The procurement of imaging equipment was further hampered by disruptions in the supply chain and logistical challenges.

However, the pandemic also underscored the importance of preclinical imaging in drug discovery and development. This increasing awareness triggered a revival in interest in preclinical imaging tools in the research of COVID-19 pathology. Therefore, despite the initial difficulties presented by COVID-19, it also prompted innovation and highlighted the importance of preclinical imaging in healthcare research.

Preclinical Imaging Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Preclinical Imaging Market Scope and Segments:

Frequently Asked Questions (FAQ):